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ABSTRACT 
Objective: Metoclopramide hydrochloride (meto) is indicated in the treatment of diabetic gastro paresis. It is also used in the treatment of pregnancy-
induced morning sickness. Present work involved the development of a chrono-modulated delivery system of meto, intended to be taken at bedtime which 
would elicit the therapeutic response early in the morning when needed the most to prevent the symptoms of diabetic gastro paresis and morning sickness. 
Methods: Immediate release tablets of meto were prepared and optimized for disintegration time and in vitro drug release. Subsequently, these 
tablets were compression coated using various ratios of glyceryl dibehenate and diluents. The resulting tablets were evaluated for disintegration 
time and in vitro drug release. Optimized formulation was subjected to accelerated stability studies for 3 mo. 
Results: The optimized immediate release tablets exhibited disintegration time of 2-3 min and more than 90% drug release within 30 min. These 
tablets when compression coated with the optimized ratio of glyceryl dibehenate and di-calcium phosphate could delay the disintegration time to 
251 min. In vitro release study of the tablets showed the lag phase of 4 h after which there was a complete drug release within 1 h. Accelerated 
stability studies indicated good physical and chemical stability of the formulation. 
Conclusion: Chrono-modulated formulation of meto could delay the release of the drug by four h. This lag in the release is expected to modulate the 
time of therapeutic response of meto early in the morning at 6-7 h interval after the administration of dosage form at bedtime. 
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INTRODUCTION 
Meto, a dopamine receptor antagonist, is indicated in the treatment 
of gastro-esophageal reflux disease, nausea and vomiting, and 
morning sickness during pregnancy [1, 2]. It is the only approved 
drug in USA for the management of diabetic gastro paresis also 
known as diabetic gastric stasis [3]. Diabetic gastro paresis is caused 
by poorly controlled type 1 and type 2 diabetes. The vagus nerve 
supplying to the stomach becomes damaged due to high blood 
glucose and lack of glucose into the cells. It is a chronic 
gastrointestinal disorder in which the gastric contents are not 
emptied in the normal way but rather at a slower rate than the 
usual. This results in severe digestive system symptoms like feeling 
of fullness very quickly upon eating, nausea, loss of appetite, 
abdominal pain and discomfort, bloating and heartburn. Lack of 
adequate gastric motility to propel the contents forward into small 
intestine can significantly hamper the absorption of glucose and other 
nutrients into the blood. Administration of anti-diabetic medicines in 
such a situation where there is inadequate glucose level in the blood 
can create serious concerns of hypoglycemia [4]. Meto stimulates the 
contractions of the stomach and intestine and helps to improve the 
gastric emptying time by acting on the dopamine receptors of the 
stomach and intestine. It also controls the feeling of nausea and vomiting 
by its action on chemo-trigger receptor zone in the brain. It helps 
regulate the sugar levels of diabetic patients suffering from gastro 
paresis by making the food available in the intestine for absorption in a 
manner such that the antidiabetic medications can work effectively [2]. 
Almost 80% of pregnant women suffer from morning sickness in the 
first trimester of pregnancy. They have to deal with severe nausea 
and bouts of vomiting in the morning which affects the appetite and 
eating, resulting in severe weakness and malnutrition. Oral therapy 
with meto is proven safe in relieving the symptoms of morning 
sickness [5]. Meto is available in various dosage forms like 
immediate release tablets, orally disintegrating tablets, solution, as 
well as controlled release formulations in the market. An extensive 
work on sustained release formulations, controlled release matrix 
tablets, flash release films, fast dissolving tablets, bucco-adhesive 
tablets, gastro-retentive delivery of meto have been reported in the 
literature [6-13]. However, all these formulations can exercise the 
therapeutic effect only after 1 to 2 h of oral administration or in a 
sustained manner depending on the type of dosage form. This would 
render the medication almost ineffective in curbing the nausea and 
vomiting that initiates as soon as waking up in the morning in the 
case of pregnant women or in preventing fluctuation in blood 
glucose levels of the diabetic patients suffering from gastro paresis.  
Chronotherapeutic drug delivery systems are gaining importance in 
the field of pharmaceutical technology as these systems reduce 
dosing frequency, toxicity and deliver a drug that matches the 
circadian rhythm of that particular disease when the symptoms are 
maximum to worse. Chrono-modulated delivery also known as the 
pulsatile delivery system is typically designed for treating 
cardiovascular conditions, asthma, arthritis wherein the symptoms are 
most intense early in the morning. Hence the Chrono modulated 
delivery is to be administered at the bed time and expected to elicit 
optimum therapeutic benefits early in the morning by virtue of lag 
time of 4 to 5 h in the drug release. Such a delivery offers the 
advantage of optimum pharmacological effect when needed the most, 
without causing the inconvenience of waking up in the middle of the 
night to administer the medicine in order to have a therapeutic effect 
early in the morning, thus improving the patient compliance [14-16]. 
With this in view, the aim of the present study was to develop a chrono-
modulated delivery system for meto that can be administered at bedtime 
and would elicit the therapeutic effect after 6-7 h, i.e. early in the 
morning, preventing morning sickness in the case of pregnant women. In 
the case of diabetic patients suffering from gastro paresis, such a 
formulation would facilitate gastric emptying of food into intestine for 
absorption so that the glucose absorbed could be effectively acted upon 
by the antidiabetic therapy preventing hypoglycemia.  
MATERIALS AND METHODS 
Chemicals and reagents 
Meto was procured from IPCA laboratories pvt. ltd., Mumbai, India; 
microcrystalline cellulose, magnesium stearate and dicalcium 
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phosphate was procured from Signet chemicals ltd, glyceryl 
dibehenate as a gift sample from Gattefosse (India) pvt. ltd., lactose 
spray dried was obtained from DFE pharma ltd. and crospovidone 
from Ashland specialties ltd. All these suppliers were based in 
Mumbai, India. 
Methods 
Preparation of immediate release core tablets of me to 
Trials to formulate the core immediate release tablets of meto were 
initiated (table 1). 
 
Table 1: Composition of immediate release tablets of meto 
Ingredients Qty in mg/tablet 
 F1 F2 F3 
Meto 11.82 11.82 11.82 
Microcrystalline cellulose  24.18 23.93 22.43 
Lactose spray dried  12 12 12 
Crospovidone XL 1.5 - - 
Crospovidone XL 10 - 1.5 2.5 
Colloidal silicon dioxide - - 0.5 
Magnesium stearate 0.5 0.75 0.75 
  
Manufacturing process 
1. Meto and lactose were sifted through 30 mesh sieve. The 
resultant material was mixed in a blender for 10 min.  
2. Microcrystalline cellulose and crospovidone XL in the case of formula 
F1, microcrystalline cellulose and crospovidone XL 10 in formula F2 and 
for formulation F3-microcrystalline cellulose, crosspovidone XL 10 and 
colloidal silicon dioxide were sifted through 30 mesh sieve and 
transferred to the blender and mixed with the blend of step 1 for 10 min. 
3. Magnesium stearate was sifted through 40 mesh sieve and 
transferred to the blend of step 2. 
4. The blend was mixed for 3 min. 
5. The lubricated blend was transferred to the hopper of the 
compression machine and tablets were compressed at the hardness 
of 2-4 kilopascals (kp) using 4.7 mm circular, biconcave, plain 
punches using Cadmach CMD4 single rotary compression machine.  
Evaluation of tablets 
Tablets of all the three batches were evaluated using following 
parameters. 
Average weight and weight variation-20 tablets were selected 
randomly and weighed. The average weight of the tablets was 
determined. These tablets were weighed individually and the weight 
variation was determined. 
Hardness was measured using Dr. Schleuniger hardness tester 
(Model 8M). 
Thickness was determined using vernier caliper (Mitutoyo, 500-197-30). 
Disintegration time was performed as per Indian Pharmacopoeia 
specifications using disintegration test apparatus (EIectrolab tablet 
disintegration test apparatus ED2L). 
Assay-Tablets, 10 numbers, were powdered. Powder equivalent to 
11.82 mg meto was dissolved in the diluents mentioned below, 
diluted suitably and subjected to assay using reverse phase HPLC 
(Agilent technologies 1260 Infinity). 
Column–C18, 5-micron packing  
Wavelength–276 nm 
Flow rate–1 ml/min 
Injection volume–5 microlitre 
Diluent–water: acetonitrile (75:25) 
Buffer solution–5.4g/litre (l) of sodium acetate in water 
Mobile phase–buffer solution: acetonitrile: tetra methyl ammonium 
hydroxide (70:30:0.2)  
In vitro release study-Tablets of the batch, F3 were subjected to 
in vitro drug release studies using USP Type 2 dissolution test 
apparatus employing 900 ml distilled water as a medium at 50 
rpm for 30 min [17]. The aliquots were analyzed by High-
performance liquid chromatography (HPLC) using the same 
method used for the assay.  
Compression coating of the core tablets 
Immediate release tablets of batch F3 were taken up for 
compression coating trials (table 2). 
 
Table 2: Formulae for the compression coating of meto immediate release tablets 
Ingredients mg/tablet 
 F4 F5 F6 F7 F8 F9 
Core tablets of F3 50 50 50 50 50 50 
Glyceryl dibehenate 127 127 127 136 156 146 
Dicalcium phosphate 110 90 167 156 136 146 
Microcrystalline cellulose 57 77 - - - - 
Colloidal silicon dioxide 3 3 3 3 3 3 
Magnesium stearate 3 3 3 5 5 5 
 
Manufacturing process 
1. Glyceryl dibehenate, dicalcium phosphate, microcrystalline 
cellulose (only in case of formula F4 and F5) and colloidal silicon 
dioxide were sifted through 30 mesh sieve and mixed in a blender 
for 15 min.  
2. Magnesium stearate was sifted through 40 mesh sieve and mixed 
with the blend of step 1 for 3 min. 
3. The coating material was compressed around the core tablets 
using 9 mm circular biconcave punches set on Cadmach press coater 
CPC 900 machine. 
Tablets were evaluated for average weight, hardness, thickness, 
disintegration time in a similar manner as conducted for core 
tablets. In vitro dissolution studies were conducted for 5 h duration, 
using similar conditions and apparatus as that for the immediate 
release tablets. The aliquots were drawn at 4, 4.5 and 5 h intervals. 
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Hardness challenge study 
The blend of batch F9 was subjected to hardness challenge during 
compression. This involved compressing half the lot at lower 
compression pressure and rest of the lot at higher pressure. 
Reproducibility trial and accelerated stability studies 
Batch F10 was prepared similarly to the composition of batch F9 in 
order to evaluate the reproducibility and the stability profile of the 
formulation. The tablets were packed in aluminum foil sachets and 
subjected to accelerated storage conditions of 40 °C/75 % RH. 
Samples were evaluated at the time intervals of 1, 2 and 3 mo. 
Statistical analysis 
One way analysis of variance (ANOVA) was employed to assess the 
difference between the assay values of initial and that of stability 
samples using Sigma Stat software (Sigma stat 2.03, SPSS). The observed 
p values of>0.05 were considered statistically significant for the test. The 
similar statistical test was applied to find a difference in the in vitro drug 
release at each time point among stability samples. 
RESULTS AND DISCUSSION 
Preparation of immediate release core tablets of meto 
The aim of the present study was to develop the chrono-modulated 
delivery system for meto using compression coating technique. For 
this, core tablets containing the drug needed to be developed 
initially which would release the drug immediately upon dissolving 
the external barrier coat. Immediate release tablets of meto were 
hence prepared by direct compression technique.  
The powder blend of formula F1 lacked appropriate flow properties 
which resulted in poor flow from the hopper onto the feed frame. Also, 
the tablet surface appeared slightly rough. It was required to improve 
the flow of the powder blend and improve the appearance. Magnesium 
stearate concentration was increased to 1.5 % and finer grade of 
crospovidone XL10 was used in batch F2. Tablets disintegrated within 
2 min. However, a small portion of core remained which took 2-3 min 
for complete disintegration. It was essential to improve the 
disintegration time since the formulation needs to release the entire 
contents after the lag period. Formulation F2 was modified by 
increasing the crospovidone content and incorporation of colloidal 
silicon dioxide. This was done in order to enable the formulation to 
draw water for complete disintegration. Thus tablets of batch F3 
showed quick disintegration time of 2-3 min without leaving behind 
the core and in vitro release of more than 90 % within 30 min (table 
3). Formula F3 was thus considered as optimized for further 
development of a chrono-modulated formulation of meto. 
Compression coating of core tablets 
Glyceryl di-behenate is a chemically inert and highly compatible 
lipid of high melting point. In combination with suitable diluents, it 
forms a good water repellant barrier layer which provides adequate 
mechanical and chemical barrier preventing the core from releasing 
the contents [18, 19]. The chrono-formulation of meto is intended to 
be administered at bedtime and elicit the therapeutic response early 
in the morning after a lag time of 6-7 h. Various combinations of 
glyceryl dibehenate, dicalcium phosphate and microcrystalline 
cellulose were tried to prepare the compression coated tablets of 
meto which would delay the release at least by 4 h. The resulting 
tablets were evaluated for hardness, thickness, disintegration time 
and the in vitro release studies. 
Tablets of batch F4 and F5 containing varying quantities of 
microcrystalline cellulose disintegrated in less than 2 h thus making 
them unsuitable for achieving the desired drug release lag time of 4 
hr. Elimination of microcrystalline cellulose in formula F6 could 
delay the disintegration time of the tablets to 3 h but failed to 
achieve the target of 4 h. Formulation F7 prepared with a higher 
quantity of glyceryl dibehenate and magnesium stearate could 
prolong the disintegration time to 210 min, however, releasing 
around 50 % of the drug at 4 h interval which was undesirable. The 
considerably higher concentration of lipid in formulation F8 
prolonged the disintegration time to more than 4 h thus curbing the 
release completely at 4 h. The tablets of this formula showed 
incomplete release at 5 h. Hence the quantity of glyceryl dibehenate 
was reduced in formula F9 which resulted in achieving desired release 
profile and the formulation was considered optimum (table 4). 
  
Table 3: Evaluation of immediate release tablets of meto 
Evaluation parameter F1 F2 F3 
Average weight (mg) 51.5±2.3 50.1±3.2 50.8±1.7 
Thickness (mm) 2.1-2.2 2.1-2.2 2.1-2.2 
Hardness (kp) 2-4 2-4 2-4 
Disintegration time (min) 5 5 2-3 
Assay (%) - - 100.4±1.3 
Drug release at 30 min (%) - - 94.3±2.3 
Values of assay and drug release are represented as mean±standard deviation, n=3, n=6 respectively 
 
Table 4: Evaluation of chrono-modulated formulations of meto 
Evaluation parameter F4 F5 F6 F7 F8 F9 
Average weight (mg) 351.5±2.2 350.1±4.6 355.5±2.4 353.0±1.4 354.3±3.2 352.1±3.7 
Thickness (mm) 3.3-3.5 3.3-3.5 3.3-3.5 3.3-3.5 3.3-3.5 3.3-3.5 
Hardness (kp) 3-5 3-5 3-5 3-5 3-5 3-5 
Disintegration time (min) 112 87 190 210 263 251 
Assay (%)  99.5±2.2 99.8±2.2 100.3±2.7 99.5±1.8 100.8±0.9 101.2±2.2 
Drug release at 4 h (%) - - - 50.8±1.8 0  0 
Drug release at 4.5 h (%) - - - 97.0±0.9 57.2±2.4 70.4±4.5 
Drug release at 5 h (%) - - - 100.2±1.9 85.3±2.1 99.1±1.4 
Values of the assay and drug release are represented as mean±standard deviation, n=3, n=6 respectively. 
 
Hardness challenge studies 
To study the impact of hardness on dissolution characteristics of the 
formulation, powder blend of batch F9 was compressed at low and 
high hardness. Tablets compressed at the low hardness of 1.5–2.5 kp 
demonstrated a failure to comply with the dissolution specifications. 
Drug release of more than 10% was observed at the time interval of 
4 h (table 5). At lower hardness, the press coated layer was not 
adequately formed and lacked the mechanical strength to withstand 
the agitation and subsequent ingress of dissolution fluid. The tablets 
compressed at hardness range of 6-7 kp complied with the 
dissolution specifications (table 5). 
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Fig. 1: In vitro release of meto from tablets of formulations F7, 
F8 and F9 
Values of in vitro drug release are represented as mean+ SD, n=6 
 
Fig. 2: Impact of hardness on in vitro drug release of 
formulation F9 
Values of in vitro drug release are represented as mean+ SD, n=6
 
Table 5: Hardness challenge studies 
Parameter Tablets of F9 with low hardness Tablets of F9 with high Hardness 
Average weight (mg) 348.5±1.9 351.5±1.8 
Hardness (kp) 1.5–2.5  6-7  
Disintegration time (min) 173  267 
Drug release at 4 h (%) 38.6±2.5  0  
Drug release at 4.5 h (%)  89.2±5.6 59.6±3.6 
Drug release at 5 h (%) 100.8±3.2 86.1±0.5 
Values of drug release are represented as mean±standard deviation, n=6 
 
Accelerated stability studies 
Stability samples of batch F10, when evaluated at various time 
intervals, showed no significant difference in appearance, hardness 
or other physical traits as compared to initial samples (table 6). 
Statistical analysis of assay values of stability samples indicated no 
significant difference. In vitro release profiles of samples when 
compared with that of initial using ANOVA exhibited no significant 
difference thus indicating good overall stability of the formulation at 
accelerated conditions. 
 
Table 6: Evaluation of stability samples of batch F10 
Test Specification Initial 1 mo  2 mo   3 mo  
Description White to off-white 
coloured circular, 
biconvex tablets 
White to off-white 
coloured circular, 
biconvex tablets 
White to off-white 
coloured circular, 
biconvex tablets 
White to off-white 
coloured circular, 
biconvex tablets 
White to off-white 
coloured circular, 
biconvex tablets 
Average weight 350 mg+3% complies complies complies complies 
Hardness 3–7kp 3–5kp 3–6kp 3–5kp 3–6kp 
Disintegration 
time 
230–300 min 256 min 266 min 263 min 270 min 
Assay 90-110%  99.8%±0.7 100.3%±1.7 99.3%±1.1 99.1%±2.0 
Drug release 4 h: NMT 10%  0% 0% 0% 0% 
4.5 h: NLT 50%  65.8%±4.1 63.9%±2.7 66.4%±3.5 62.6%±3.2 
5 h: NLT 85%  97.2%±3.8 93.2%±1.4 95.2%±2.5 91.5%±1.9 
Values of assay and drug release are represented as mean±standard deviation, n=3, n=6 respectively 
 
The reported literature on meto involves development of fast release 
oral films, mouth dissolving tablets [10, 11] which would release the 
drug quickly after oral administration, however, the time to peak 
plasma level (tmax) would still be around 2 h and hence the drug would 
not be able to elicit therapeutic response immediately upon 
administration which is needed in treating morning sickness or 
gastroparesis. Review of literature also indicates the development of 
modified release formulations of meto which would release the drug 
slowly over a period of 12 h [6-9, 12, 13]. Such formulations could 
reduce the symptoms to some extent; however the optimum response 
may not be achieved since the plasma levels of the drug would be 
lower as compared to the ones attained in the case of chrono-
modulated formulation, which would release the drug at once and 
exert highest therapeutic response at the time when needed the most.  
CONCLUSION 
Compression coated tablets of meto prepared using glyceryl 
dibehenate as a release modifier could delay the in vitro release of the 
drug up to 4 h and subsequently exhibited complete release within 1 h. 
This chrono-modulated formulation of meto when administered at 
bedtime, can thus be expected to achieve maximum therapeutic effect 
early in the morning to relieve the pregnant women from symptoms of 
morning sickness and prevent the serum glucose level fluctuations in 
diabetic patients suffering from gastroparesis. 
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